If you have been reading about half-life and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
In March 2020, the release of 15.ai, a free web application created by an anonymous MIT researcher that could generate convincing character voices using minimal training data, was one of the earliest publicly available uses for generative AI. The platform is credited as the first mainstream service for audio deepfakes. In 2021, DALL-E, a closed-source transformer-based generative model developed by OpenAI, drew widespread attention to text-to-image generation. Other projects, including open-source approaches such as VQGAN+CLIP and DALL·E Mini (later renamed Craiyon), made similar systems more accessible to the public. Dream by Wombo was released at the end of 2021, followed by the releases of Midjourney and Stable Diffusion in 2022. In November 2022, ChatGPT was released to the public. By 2023, it popularized generative AI for general-purpose text-based tasks.
== Release and commercial performance == Upon its release in September 1992, Dirt peaked at number six on the Billboard 200 and charted for 102 weeks, ending at number 196 in the week of September 24, 1994. Dirt granted Alice in Chains international recognition, and the album was certified 5× platinum in the United States, platinum in Canada and gold in the UK. The album had sold 3,358,000 copies in the United States as of 2008. It is the band's most commercially successful album. A remastered reissue of the album was released on vinyl on November 23, 2009. Dirt included the top-30 singles "Would?", "Them Bones", "Angry Chair", "Rooster", and "Down in a Hole", all of which had accompanying music videos. The album returned to the top 10 of the Billboard 200 chart at No. 9 following the release of its 30th anniversary reissue on September 23, 2022.
Like agonists, inverse agonists have their own unique ways of inducing pharmacological and physiological responses depending on many factors, such as the type of inverse agonist, the type of receptor, mutants of receptors, binding affinities and whether the effects are exerted acutely or chronically based on receptor population density. Because of this, they exhibit a spectrum of activity below the Intrinsic activity level. Changes in constitutive activity of receptors affect response levels from ligands like inverse agonists. To illustrate, mechanistic models have been made for how inverse agonists induce their responses on G protein-coupled receptors (GPCRs). Many types of Inverse agonists for GPCRs have been shown to exhibit the following conventionally accepted mechanism. Based on the Extended Ternary complex model, the mechanism contends that inverse agonists switch the receptor from an active state to an inactive state by undergoing conformational changes. Under this model, current thinking is that the GPCRs can exist in a continuum of active and inactive states when no ligand is present. Inverse agonists stabilize the inactive states, thereby suppressing agonist-independent activity. However, the implementation of 'constitutively active mutants' of GPCRs change their intrinsic activity. Thus, the effect an inverse agonist has on a receptor depends on the basal activity of the receptor, assuming the inverse agonist has the same binding affinity (as shown in the figure 2).
==== Responsiveness to ovarian steroids ==== Dimorphism is also found in physiological and behavioral responses to ovarian steroids in adults, where males and females respond to these hormones differently. For example, estrogen receptor sensitivity for different sets of neurons is dimorphic already early on in development. Hypothalamic dimorphism underlies some known behavioral differences in mice, and has known physiological effects in humans, e.g. affecting thermoregulation and metabolism. Although human hypothalami exhibit various sex differences, it is not certain which behaviors are caused, predisposed, and not caused by these. In addition to confounding environmental factors, the hypothalamus also contributes to dimorphic human behaviors where the hypothalamus does not itself cause dimorphism, but rather exhibits conditional, dimorphic responses as part of greater pathways, such as the HPG-axis or the HPA-axis. Estrogen and progesterone can influence gene expression in particular neurons or induce changes in cell membrane potential and kinase activation, leading to diverse non-genomic cellular functions. Estrogen and progesterone bind to their cognate nuclear hormone receptors, which translocate to the cell nucleus and interact with regions of DNA known as hormone response elements (HREs) or get tethered to another transcription factor's binding site. Estrogen receptor (ER) has been shown to transactivate other transcription factors in this manner, despite the absence of an estrogen response element (ERE) in the proximal promoter region of the gene.
Sources: en.wikipedia.org
== Misconceptions == Drosophila is often referred to as a pest due to its tendency to live in human settlements where fermenting fruit is found. Flies may collect in homes, restaurants, stores, and other locations. The name and behavior of this species of fly have led to the misconception in Australia and elsewhere that it is a biological security risk. While other "fruit fly" species do pose a risk, D. melanogaster is simply attracted to fruit that is already rotting; it does not cause the fruit to rot.
=== Market types === Items on a typical centralized darknet market are listed from a range of vendors in an eBay-like marketplace format. Virtually all such markets have advanced reputation, search and shipping features similar to Amazon.com. By 2015, some of the most popular vendors had their own dedicated online shops separate from the large marketplaces. Individual sites had returned to operating on the clearnet, with mixed success. Some criminal internet forums such as the defunct Tor Carding Forum and the Russian Anonymous Marketplace function as markets with trusted members providing escrow services, and users engaging in off-forum messaging. In May 2014 the "Deepify" service attempted to automate the process of setting up markets with a SAAS solution; however, this closed a short time later. Following repeated problems associated with centralized infrastructure, a number of decentralized marketplace software alternatives were set up using blockchain or peer-to-peer technologies, including OpenBazaar and Bitmarkets,
Compton had recently founded the American Research and Development Corporation (ARD) to spur the formation of new post-war industries. He introduced the founders to ARD's president, Georges Doriot. Doriot predicted the cancer treatment machines would be a commercial failure. Nevertheless, he perceived HVEC's leaders to be technically capable, and Compton persuaded him that ARD should have a startup with clear human benefits. Among more than 400 applications, Doriot selected the firm among ARD's first three investments. He offered the founders $200,000 in initial capitalization, leaving half the equity to them and their staff consultants. Compton arranged for HVEC to exclusively license MIT's Van de Graaff and Trump patents. Both Compton and Doriot served on the new company's board.
Sources: en.wikipedia.org
The tracer 68Ga-Trivehexin showed an uptake of SUVmax = 5.53 in fibrotic lung tissue and enabled a differentiation between fibrotic and non-fibrotic lung areas in PET/CT images. 68Ga-Trivehexin yielded clear PET signals in IPF lesions which were PET-negative using the standard metabolic PET tracer 18F-FDG.
A number of very specialised chain types have emerged over recent years. These include chains made of steel alloys optimised for cutting in extremely cold conditions, chains with tungsten carbide teeth for very dirty conditions and rescue work, ripping chains with altered blade geometry for making ripping cuts, and milling chains for chainsaw mills. Chain mortisers, used to cut the mortice of large mortice and tenon timber framing, use a number of chains, riveted side-by-side. They are used with a vertical tip-first plunge. Owing to the difficulty of resharpening the multiple teeth, these are usually made of long-lasting tungsten carbide.
=== Sex differences === There are significant sex differences in political views among Generation Z, with young women under 30 years of age being broadly left-wing and young men being right-leaning on a variety of issues from immigration to sexual harassment. A gender gap has been observed since 1980, when women were more likely to vote for the Democratic Party and men for the Republican Party. But this gap has widened during the 2010s and 2020s. According to Gallup, the gap as of early 2024 among voters below the age of 30 was 30 percentage points. Some young men believe that women's progress has come at their expense, that it should be acceptable to discuss men's mental health issues, that men's economic concerns have not been addressed, or that most politicians have ignored them. Facing despair and political homelessness, many young men find Donald Trump an appealing alternative. In contrast, many young women became politically active because of the 2016 presidential campaign of Secretary of State Hillary Clinton, the me-too movement, the Dobbs v. Jackson decision on abortion by the Supreme Court, and the 2024 presidential campaign of Vice President Kamala Harris (after incumbent President Joe Biden announced he would not seek re-election). In fact, Harris managed to secure the support of many young female voters, who previously only reluctantly voted for Biden or did not vote at all, and her support among women has been rising faster than among young men.
== Acquisitions == 2000: Icon acquired UK-based regulatory consultancy, YRCR Ltd.; Central Laboratory in New York; and bioanalytical consultancy, Pacific Research 2002: Icon acquired clinical research provider, BPA. 2003: Icon acquired Medieval, a UK-based Phase I facility, and US consulting firm, Globomax 2004: Icon acquired medical imaging specialist, Beacon Bioscience Inc. 2006: Icon acquired outcomes research and health economics specialist, Ovation Research Group 2007: Icon acquired European staffing group, DOCS International 2008: Icon acquired US phase I provider, Healthcare Discoveries and US bioanalytical lab, Prevalere Life Sciences 2009: Icon acquired Veeda Laboratories, a UK biomarker lab 2010: Icon acquired Timaq Medical Imaging Inc.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.